Financial Performance - The company reported a sales revenue of 325 million yuan, a decrease of 10.81% compared to the same period last year[3]. - The net profit for the reporting period was negative, indicating continued pressure on the company's performance[3]. - The company’s core business and financial indicators have not experienced significant adverse changes, aligning with industry trends[3]. - The company’s operating revenue for 2024 was ¥324,815,960.70, a decrease of 10.81% compared to ¥364,175,426.91 in 2023[26]. - The net profit attributable to shareholders for 2024 was -¥144,842,559.91, showing an improvement of 63.69% from -¥398,892,799.55 in 2023[26]. - The total assets at the end of 2024 were ¥1,149,607,757.17, a decrease of 13.71% from ¥1,332,220,277.68 at the end of 2023[27]. - The total net assets attributable to shareholders at the end of 2024 were ¥929,233,931.83, down 8.96% from ¥1,020,667,878.29 at the end of 2023[27]. - The company achieved a total revenue of 324.82 million yuan, a decrease of 10.81% compared to the previous year[53]. - The company reported a weighted average return on equity of -15.04% for 2024, an improvement of 18.68% from -33.72% in 2023[27]. Research and Development - Research and development (R&D) investment was 162 million yuan, a significant decrease of 63.77% year-on-year[3]. - The company plans to maintain an appropriate level of R&D investment in the near future due to the ongoing project demands[5]. - The company is focused on optimizing its R&D project selection and enhancing clinical development efficiency[6]. - The company has a research and development team of 104 people, accounting for 21.14% of total employees, with 67.31% holding master's degrees and 23.08% holding doctoral degrees[58]. - R&D investment amounted to 162.29 million yuan, accounting for 49.97% of total revenue, a significant decrease of 63.77% compared to the previous year[53]. - The company is currently conducting clinical trials for multiple drugs, including STSA-1002 and STSP-0902, with various phases of clinical research ongoing[48]. - The company’s product pipeline focuses on innovative biopharmaceuticals targeting infectious diseases, respiratory and critical care, autoimmune diseases, and neurological disorders[55]. - The company aims to enhance its research and development capabilities and has established a comprehensive quality management and marketing system[44]. Market and Industry Trends - The pharmaceutical industry faces challenges from external policies such as centralized procurement and medical reform, impacting production and sales[4]. - The Chinese biopharmaceutical industry is recognized as a strategic emerging industry, driven by increasing healthcare demands due to aging population and urbanization[37]. - The government has introduced policies to support the development of innovative drugs, marking a new phase for the Chinese innovative drug industry[38]. - The company anticipates significant growth opportunities in the domestic pharmaceutical industry due to the aging population and increasing market demand[122]. Clinical Trials and Product Development - The company has made progress in several clinical trials, including BDB-001 for HS, STSA-1201 for asthma, and STSP-0601 for hemophilia A or B, with STSP-0601 receiving orphan drug designation from the FDA[45]. - The company is actively communicating with the CDE to clarify the research and market application paths for its products[45]. - The company is focusing on the clinical development of innovative biopharmaceuticals targeting neurological diseases, respiratory and critical care, infectious diseases, and autoimmune diseases[63]. - The company’s product STSP-0902 for asthenozoospermia is in the Ia phase of clinical trials[48]. Governance and Compliance - The company has established a comprehensive governance structure, including a shareholders' meeting, board of directors, supervisory board, and management team, ensuring effective operation and compliance with relevant laws and regulations[133]. - The board of directors consists of seven members, including three independent directors, meeting the legal requirements for composition and ensuring objective decision-making[137]. - The company emphasizes investor relations management, providing multiple communication channels and ensuring timely and accurate information disclosure[140]. - The company has established various internal control systems to improve governance levels and comply with regulatory requirements[134]. - The company respects the rights of stakeholders and emphasizes social responsibility, promoting balanced interests among shareholders, employees, and society[141]. Strategic Initiatives and Investments - The company plans to absorb and merge its wholly-owned subsidiaries, De Feng Rui and Zhejiang Shu Tai Shen, as part of its strategic initiatives[148]. - The company has a future outlook of expanding its market presence through strategic acquisitions and investments in biotechnology firms[102]. - The company is committed to ensuring the feasibility and effectiveness of its investment projects, with ongoing assessments of project progress[101]. - The company has initiated a new project with an expected investment of 7,000 million, currently at 6,820 million, indicating a 97.43% completion rate[102]. Cash Flow and Financial Management - The cash generated from operating activities was -¥63,682,894.36, an improvement of 72.11% compared to -¥228,319,173.72 in 2023[26]. - Operating cash inflow decreased by 25.30% to ¥354,248,442.60 compared to ¥474,247,879.57 in 2023[86]. - Operating cash outflow decreased significantly by 40.51% to ¥417,931,336.96 from ¥702,567,053.29 in the previous year[86]. - The net increase in cash and cash equivalents improved by 82.41%, resulting in a decrease of ¥31,627,772.87 from a decrease of ¥179,810,721.71 in the previous year[86]. Talent and Human Resources - The company recognizes the risks associated with innovative drug development, including high investment and long development cycles, which may impact business and financial conditions[125]. - The company faces risks related to the shortage of high-quality technical and management talent, which is crucial for its development[126]. - The company will implement a talent cultivation system and employee equity incentive plans to attract and retain high-quality talent[126]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[197]. - The company aims to accelerate the progress of its pipeline projects currently in Phase I and II/III clinical trials to advance to the next stage in 2025[123]. - The company plans to enhance its marketing capabilities and explore new business models to improve sales and profitability[123].

证券代码：300204 证券简称：舒泰神 公告编号：2025-010 关于子公司增资扩股暨引入投资者及股权转让的进展公告（二） 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"） 于 2024 年 12 月 23 日召开第六届董事会第五次会议、第六届监事会第五次会议， 审议通过了《关于子公司增资扩股暨引入投资者及股权转让的议案》，同意江苏 贝捷泰生物科技有限公司（以下简称"贝捷泰"）增资扩股暨引入投资者及股权 转让事项，并放弃增资扩股的优先认缴出资权、放弃股权转让的优先购买权。该 事项已经独立董事专门会议审议通过。具体内容详见公司于 2024 年 12 月 24 日 披露于巨潮资讯网的《第六届董事会第五次会议决议公告》（公告编号 2024-48- 01）、《第六届监事会第五次会议决议公告》（公告编号 2024-48-02）、《关于子公 司增资扩股暨引入投资者及股权转让的公告》（公告编号 2024-48-03）。 舒泰神（北京）生物制药股份有限公司 二、交易进展 公司于 2025 年 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-009 舒泰神（北京）生物制药股份有限公司 关于子公司增资扩股暨引入投资者及股权转让的进展公告 二、交易进展 根据前期双方已签订交易协议的约定，投资款分两次交割，首次 30%，"甲 方（无锡金易原力股权投资合伙企业（有限合伙）（以下简称"金易原力基金"）） 应分别向（a）目标公司（贝捷泰）指定的银行账户缴纳 30%的增资款，即 4,000 万元的价款作为首期增资款（以下简称"首期增资款"），其中 159.99 万元作为实 缴的 30%新增出资额，3,840.01 万元计入目标公司的资本公积；及（b）乙方（舒 泰神）指定的银行账户支付 30%的转让款，即 2,000 万元的价款作为首期转让款 （以下简称"首期转让款"，与首期增资款合称为"首期投资款"）。" 近日，金易原力基金根据交易协议的约定，已完成首期投资款的支付。其中， 贝捷泰收到金易原力基金首期增资款 4,000 万元，舒泰神收到金易原力基金首期 转让款 2,000 万元。 三、本次交易目的和对公司的影响 本次交易是为更好支持公司发展，满足经营发展需要，为在研项目推进提供 支持，不会对公司的财 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-008 2025 年 01 月熠昭科技与周志文先生签署了《熠昭（北京）医药科技有限公 司与周志文关于舒泰神（北京）生物制药股份有限公司之股份转让协议之补充协 议》（以下简称"《补充协议》"），双方就原协议约定的部分条款进行了补充修改。 具体内容详见公司于 2025 年 01 月 24 日在巨潮资讯网披露的《关于控股股东和 一致行动人之间进行权益变动的进展暨签署补充协议的公告》（公告编号 2025- 004）。 舒泰神（北京）生物制药股份有限公司 关于控股股东和一致行动人协议转让完成过户登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"） 近日收到控股股东熠昭（北京）医药科技有限公司（以下简称"控股股东"或"熠 昭科技"）及其一致行动人周志文先生的通知，熠昭科技与周志文先生的协议转 让事项已经在中国证券登记结算有限公司深圳分公司办理完成过户登记手续，并 取得《证券过户登记确认书》，现将具体情况公告如下： 一、本次协议转让的基本情 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-007 | | | | 累计质 | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 持股数 | 持股比 | 押股份 | 占其所 | 占公司 | 已质押股 | 占已质 | 未质押股 | 占未 | | 名称 | 量 （万股） | 例 | 数量 | 持股份 | 总股本 | 份限售和 | 押股份 | 份限售和 | 质押 | | | | | （万股） | 比例 | 比例 | 冻结数量 | 比例 | 冻结数量 | 股份 | | | | | | | | （万股） | | （万股） | 比例 | | 香塘集团 | 3,669.50 | 7.68% | 3,255.00 | 88.70% | 6.81% | 0 | 0% | 0 | 0% | | | 08 | | 00 | | | | | | | 股东 名称 是否为控股股东 或第一大股东及 其一致行动人 本次解除质押 股数（万股） 占其所持 股份比例 占公司总 股本比例 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-006 舒泰神（北京）生物制药股份有限公司 董事会 2025 年 02 月 13 日 舒泰神（北京）生物制药股份有限公司（以下简称"公司""舒泰神"）子公 司北京三诺佳邑生物技术有限责任公司（以下简称"三诺佳邑"）于近日收到由 北京市科学技术委员会、北京市财政局、国家税务总局北京市税务局联合颁发的 《高新技术企业证书》，三诺佳邑通过高新技术企业的认定，现将有关情况公告 如下： 三诺佳邑于 2024 年顺利通过高新技术企业的认定，并于近日取得《高新技 术企业证书》，证书编号为 GR202411007668，发证时间为 2024 年 12 月 31 日， 有效期为三年。 根据《中华人民共和国企业所得税法》及国家对高新技术企业税收优惠等相 关规定，三诺佳邑将连续三年享受高新技术企业的相关税收优惠政策（按 15% 的税率缴纳企业所得税）。 特此公告 舒泰神（北京）生物制药股份有限公司 关于子公司三诺佳邑通过国家高新技术企业认定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-005 舒泰神（北京）生物制药股份有限公司 法定代表人：王超 注册资本：9,000 万人民币 住所：无锡市惠山区玉祁街道唐平路 66 号 1 号楼 4-1 关于子公司贝捷泰完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司""舒泰神"）于近 日收到子公司江苏贝捷泰生物科技有限公司（以下简称"贝捷泰"）的通知，因 公司经营发展需要，贝捷泰对公司注册地址进行变更，并于近日完成了工商变更 登记，取得无锡市惠山区数据局换发的《营业执照》。 贝捷泰变更后的《营业执照》登记的具体信息如下： 统一社会信用代码：91320206MAE6KA557W 公司类型：有限责任公司 成立日期：2024 年 11 月 29 日 经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；生物基材料技术研发；货物进出口；技术进出口；进出口代理（除 依法须经批准的项目外，凭营业执照依法自主开展经营活动） 特此公告 舒泰神（北 ...

一、《补充协议》主要内容 （一）协议转让双方 证券代码：300204 证券简称：舒泰神 公告编号：2025-004 舒泰神（北京）生物制药股份有限公司 关于控股股东和一致行动人之间进行权益变动的进展暨签署补充协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"） 于 2024 年 09 月 20 日在巨潮资讯网披露了《关于控股股东和一致行动人之间进 行权益变动的提示性公告》（公告编号 2024-33-01）及《北京市康达律师事务所 关于周志文先生免于以要约方式增持股份事宜的法律意见书》。 舒泰神近日收到控股股东熠昭（北京）医药科技有限公司（以下简称"控股 股东"或"熠昭科技"）及其一致行动人周志文先生的通知，熠昭科技与周志文 先生于近日签署了《熠昭（北京）医药科技有限公司与周志文关于舒泰神（北京） 生物制药股份有限公司之股份转让协议之补充协议》）（以下简称"《补充协议》"）， 双方就原协议约定的部分条款进行了补充修改，现将相关信息公告如下： 修改为"本协议自甲方法定代表人或其委托代理人签字 ...

以2024年上半年为例，舒泰清、苏肽生与阿司匹林肠溶片合计为舒泰神带来销售收入1.80亿元，占总营 收超过98%。当期，仅研发费用与销售费用合计就达1.33亿元，占总营收的73%。 2021-2023年间，舒泰神分别实现营收5.84亿元、5.49亿元、3.64亿元，对应研发投入分别为3.63亿元、 3.63亿元、4.12亿元，占总收入的比例为62.04%、66.09%、113.20%，同期销售费用分别为2.86亿元、 2.65亿元、1.82亿元，与研发费用相比有下降趋势。 而舒泰神的研发费用之所以连年处于高位，主要原因在于其有多款创新药物同时处于临床试验阶段。截 至2024年上半年，舒泰神的在研适应症超过14个，药物种类包括单抗药物、蛋白药物、基因药物，其中 有4个适应症进入临床III期。 事实上，在2023年的时候，舒泰神因为仍在开展多项与COVID-19相关的适应症研究，其在研管线逼近 20条，且部分COVID-19的管线还处于国际多中心临床III期。进入2024年，舒泰神一口气将与COVID-19 相关的在研管线终止，一定程度缓解了研发投入的压力。 此外，为了整合资源及降本增效，舒泰神还在2024年完成 ...

Financial Performance - The company expects a net loss attributable to shareholders of approximately 14,766.76 million CNY for the year 2024, compared to a loss of 39,889.28 million CNY in the previous year[3]. - The projected operating revenue for 2024 is around 29,215.00 million CNY, reflecting a decrease of approximately 19.78% compared to the previous year's revenue of 36,417.54 million CNY[3]. - The net loss after deducting non-recurring gains and losses is estimated at 15,870.58 million CNY for 2024, down from 40,630.28 million CNY in the prior year[3]. - The basic earnings per share are projected to be a loss of 0.31 CNY per share, compared to a loss of 0.84 CNY per share in the previous year[3]. Business Strategy - The company is actively expanding its marketing and market exploration efforts while focusing on new product development, despite a decline in main business revenue due to external factors[5]. - The company has established a subsidiary, Jiangsu Beijietai Biotechnology Co., Ltd., funded by certain R&D projects, and is reversing deferred tax assets related to prior years' deductible losses[5]. Non-Recurring Items - Non-recurring gains and losses for 2024 are expected to be approximately 1,003.47 million CNY, with specific figures to be disclosed in the annual report[5]. Audit and Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with no discrepancies reported between the company and the auditors regarding the earnings forecast[4].